ORCID as entered in ROS
https://orcid.org/0000-0002-7380-1170
Select Publications
Conference Papers
, 2024, 'Cost-Effective Space Based Platforms for Bushfire Monitoring', in IEEE Aerospace Conference Proceedings, http://dx.doi.org/10.1109/AERO58975.2024.10521271
, 2022, 'A phase 1 dose-escalation study of the ABN401 (c-MET inhibitor) in patients with solid tumors.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, presented at
, 2022, 'A phase I dose-escalation and expansion study of HBM4003, an anti-CTLA-4 heavy chain only monoclonal antibody, in patients with advanced solid tumors', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, presented at
, 2022, 'Phase 1 study of ADG126, a novel masked anti-CTLA-4 SAFEbody, that combines tumor-localized activation with strong T-reg depletion and soft ligand blocking in patients with advanced solid tumors.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, pp. E17601 - E17601, presented at
, 2021, 'A phase I dose-escalation study of HBM4003: An anti-CTLA-4 heavy-chain-only mAb', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, pp. S855 - S855, presented at
, 2020, 'MIR-10B AS A MARKER FOR DISSEMINATED DISEASE IN RDEB-LINKED SCCS', in ACTA DERMATO-VENEREOLOGICA, ACTA DERMATO-VENEREOLOGICA, pp. 60 - 61, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000568327600162&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2020, 'MIRNA-10B MARKS AGGRESSIVE SQUAMOUS CELL CARCINOMAS IN RDEB', in ACTA DERMATO-VENEREOLOGICA, ACTA DERMATO-VENEREOLOGICA, pp. 35 - 36, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000568327600097&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2019, 'A phase I dose escalation and dose expansion study of the anti-programmed cell death-1 (PD-1) antibody AK105.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at
, 2018, 'Longitudinal analysis of circulating biomarkers to monitor advanced EGFR mutated (EGFR+) non-small cell lung cancer (NSCLC)', in Annals of oncology : official journal of the European Society for Medical Oncology, pp. viii660, http://dx.doi.org/10.1093/annonc/mdy303.033
, 2018, 'Abstract B183: The WEE1 inhibitor AZD1775 in combination with chemotherapy in Asian patients with advanced solid tumors: a phase Ib study', in Molecular Cancer Therapeutics, American Association for Cancer Research (AACR), pp. B183 - B183, http://dx.doi.org/10.1158/1535-7163.targ-17-b183
, 2017, 'Docetaxel-related fatigue in men with metastatic prostate cancer: a descriptive analysis', in Supportive Care in Cancer, pp. 2871 - 2879, http://dx.doi.org/10.1007/s00520-017-3706-8
, 2017, 'Serum microRNA expression during neoadjuvant chemoradiation for rectal cancer.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at
, 2016, 'Abstract 2047: Pharmacokinetics (PK) of CRLX301, a novel nanoparticle-drug conjugate (NDC) containing the payload docetaxel, in patients with refractory solid tumors', in Cancer Research, American Association for Cancer Research (AACR), pp. 2047 - 2047, http://dx.doi.org/10.1158/1538-7445.am2016-2047
, 2016, 'A phase 1 study of CRLX301, a novel nanoparticle-drug conjugate (NDC) containing docetaxel (DOC), in patients with refractory solid tumors.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at
, 2016, 'Change in serum microRNA expression during neoadjuvant chemoradiation for rectal cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, LA, New Orleans, presented at
, 2015, 'Circulating tumour cell release in the peri-operative setting during curative colorectal cancer surgery', in Annals of Oncology, Oxford University Press (OUP), Barcelona, SPAIN, presented at
, 2015, 'Impact of crossover and baseline prognostic factors on overall survival (OS) with abiraterone acetate (AA) in the COU-AA-302 final analysis.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, FL, Orlando, presented at
, 2014, 'Polo-like kinase 1 as a biomarker in rectal cancers', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at
, 2014, 'Association of alkaline phosphatase (ALP) with clinical outcomes in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at
, 2014, 'A PHASE II STUDY OF SEQUENTIAL THERAPY WITH PAZOPANIB FOLLOWED BY EVEROLIMUS IN METASTATIC RENAL CELL CANCER - STUDY UPDATE', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 65 - 65, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000339716500059&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2014, 'POLO-LIKE KINASE 1 AS A BIOMARKER IN RECTAL CANCER', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 60 - 60, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000339716500045&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2013, 'Long-term safety and efficacy analysis of abiraterone acetate (AA) plus prednisone (P) in study COU-AA-302for metastatic castration-resistant prostate cancer', in BJU INTERNATIONAL, WILEY-BLACKWELL, pp. 13 - 13, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000321969100032&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2013, 'Long-term safety and efficacy analysis of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (COU-AA-302)', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at
, 2013, 'Reducing invasion potential of cervical cancer cells via targeted knockdown of c-Jun', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at
, 2013, 'Updated interim analysis (IA) of COU-AA-302, a randomized phase III study of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, FL, Orlando, presented at
, 2012, 'OUTCOMES OF ETHNIC MINORITY GROUPS WITH NODE-POSITIVE, NON-METASTATIC BREAST CANCER IN A TERTIARY REFERRAL CENTRE IN SYDNEY', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, AUSTRIA, Vienna, pp. 100 - 100, presented at
, 2012, 'Phase III, randomised, double-blind, placebo-controlled study of Modafinil for fatigue in patients treated with Docetaxel-based chemotherapy', in Asia-Pacific Journal of Clinical Oncology, Blackwell Publishing Asia Pty Ltd, Australia, pp. 26 - 26, presented at
, 2012, 'Phase I study of everolimus in combination with fluvastatin and zoledronic acid in patients with solid tumours', in Journal of clinical oncology - official journal of the American Society of Clinical Oncology, American Society of Clinical Oncology, New York, pp. e13585 - e13585, presented at
, 2012, 'Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at
, 2012, 'Modafinil for fatigue associated with docetaxel-based chemotherapy: A randomized controlled trial.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at
, 2012, 'Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, Chicago, IL, presented at
, 2012, 'Association of Radiographic Progression-Free Survival (Rpfs) adapted from Prostate Cancer Working Group 2 (Pcwg2) Consensus Criteria (Apcwg2) with Overall Survival (Os) in Patients (Pts) with Metastatic Castration-Resistant Prostate Cancer (Mcrpc): Results from Cou-Aa-302', in Annals of Oncology, Oxford Univ Press, Oxford, England, pp. 23 294-295; 9 SEP 2012, presented at
, 2012, 'hENT1 expression in human urothelium; evaluating hENT1 prognostic potential for intravesical Gemcitabine treatment outcome in patients with superficial urothelial carcinoma', in BJU International, Darwin, pp. 109 40-40; 4 SI APR 2012, presented at
, 2012, 'Outcomes of ethnic minority groups with node-positive, non-metastatic breast cancer in a tertiary referral centre in Sydney', in Annals of Oncology, Oxford Univ Press, Oxford, England, pp. 23 100-100; 9 SEP 2012, presented at
, 2012, 'Tumour:node ratio in node-positive, non-metastatic breast cancer', in Asia-Pacific Journal of Clinical Oncology, Blackwell Publishing Asia, Australia, pp. 8 37-37; 2 SI AUG 2012, presented at
, 2011, 'Increased expression of EGFR in squamous cell carcinoma in recessive dystrophic epidermolysis bullosa and response to Cetuximab', in Australasian Journal of Dermatology, New South Wales : Wiley-Blackwell, Australia, pp. 32 - 32, presented at
, 2010, 'A RANDOMIZED, PHASE 2 STUDY OF PACLITAXEL (P) AND CARBOPLATIN (C) +/- CONATUMUMAB (CON) FOR FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC)', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, ITALY, Milan, pp. 137 - 137, presented at
, 2010, 'Fatigue after adjuvant therapy for breast cancer influences health care utilisation and perceived needs', in Grunberg SM (ed.), Journal of Clinical Oncology, American Society of Clinical Oncology, Virginia USA, pp. 647s, presented at
, 2010, 'Late fatigue after adjuvant therapy for early breast cancer is largely unrelated to cancer or its treatment: 5 year follow-up of a prospective cohort study', in Asia-Pacific Journal of Clinical Oncology, Blackwell Publishing Asia Pty Ltd, Australia, pp. 53 - 60, presented at
, 2009, 'CRP predicts tolerance of treatment and overall survival with weekly carboplatin-paclitaxel and concomitant irradiation for locally advanced non-small cell lung cancer', in Journal of Thoracic Oncology, Lippincott Williams & Wilkins, USA, pp. S864 - S865, presented at
, 2009, 'Cytidine Deaminase c.79A > C Polymorphism Affected Optimal Dose Delivery of Gemcitabine', in Drug Metabolism Reviews, Marcel Dekker Inc, New York, NY, USA, pp. 231 - 232, presented at
, 2009, 'Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies', in Medical Oncology, Humana Press Inc, Totowa, NJ, USA, presented at
, 2008, 'A prospective cohort study of fatigue after adjuvant therapy for breast cancer', in Psycho - Oncology, John Wiley & Sons Ltd, Chichester, W Sussex, England, pp. S36 - S37, presented at
, 2008, 'A study of rare presentations of metastatic melanoma', in Australasian Journal of Dermatology, New South Wales : Wiley-Blackwell, Australia, pp. A75 - A76, presented at
, 2007, 'Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000455043701159&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2007, 'Lessons learnt in evaluating the target of drug action in a phase 1 trial of oral albendazole –a benzimidazole carbamate anti-helminthic- in patients with cancer refractory to conventional treatments.', in Asia-Pacific Journal of Clinical Oncology, Blackwell Publishing Asia, Australia, pp. A79 - A79, presented at
Filter by type
https://orcid.org/0000-0002-7380-1170